Psoriasis severity and hypothalamic-pituitary-adrenal axis function: results from the CALIPSO study
Carregando...
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2014
Editora
ASSOC BRAS DIVULG CIENTIFICA
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, v.47, n.12, p.1102-1106, 2014
Resumo
Psoriasis is a chronic inflammatory disease that significantly impacts life quality, being associated with stress and mental disorders. We investigated whether the activity of the hypothalamic-pituitary-adrenal (HPA) axis was associated with psoriasis severity, daily life stress and anxiety, and depressive symptoms. In this ancillary study, which was part of the CALIPSO (coronary artery calcium in psoriasis) study, saliva was collected from 102 patients with psoriasis immediately upon awakening, 30, and 60 min after awakening, at 2:00 pm and at bedtime (five time points) to determine salivary cortisol levels. We used Pearson's correlation coefficient to evaluate the association of clinical and psychopathological variables with HPA activity. We found a direct correlation between bedtime cortisol and psoriasis severity evaluated by the psoriasis area severity index (PASI; r=0.39, P<0.001). No correlations between other clinical and psychopathological variables or with other cortisol assessments were observed. The findings indicated that HPA dysfunction may be present in psoriasis, as bedtime cortisol was correlated with psoriasis severity. Our study is limited by the lack of a control group; therefore, we were not able to explore whether these cortisol values were different compared with a concurrent, healthy sample.
Palavras-chave
Psoriasis, Cortisol, HPA function, Clinical study
Referências
- Amatya B, 2011, BRIT J DERMATOL, V164, P1023, DOI 10.1111/j.1365-2133.2011.10241.x
- ARNETZ BB, 1985, PSYCHOSOM MED, V47, P528
- Basavaraj KH, 2011, INT J DERMATOL, V50, P783, DOI 10.1111/j.1365-4632.2010.04844.x
- Carrion VG, 2010, BIOL PSYCHIAT, V68, P491, DOI 10.1016/j.biopsych.2010.05.010
- Dominguez PL, 2013, J EUR ACAD DERMATOL, V27, P1163, DOI 10.1111/j.1468-3083.2012.04703.x
- Evers AWM, 2010, BRIT J DERMATOL, V163, P986, DOI 10.1111/j.1365-2133.2010.09984.x
- Finlay AY, 2005, BRIT J DERMATOL, V152, P861, DOI 10.1111/j.1365-2133.2005.06502.x
- FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
- Gelfand JM, 2005, J AM ACAD DERMATOL, V53, P573, DOI 10.1016/j.jaad.2005.03.046
- Golden SH, 2013, PSYCHONEUROENDOCRINO, V38, P2720, DOI 10.1016/j.psyneuen.2013.06.032
- Golden SH, 2011, EUR J EPIDEMIOL, V26, P511, DOI 10.1007/s10654-011-9585-2
- Gorenstein C, 2000, ESCALAS AVALIACAO CL
- Hellhammer DH, 2009, PSYCHONEUROENDOCRINO, V34, P163, DOI 10.1016/j.psyneuen.2008.10.026
- HOLMES TH, 1967, J PSYCHOSOM RES, V11, P213, DOI 10.1016/0022-3999(67)90010-4
- KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2
- Kudielka BM, 2003, PSYCHOSOM MED, V65, P313, DOI 10.1097/01.PSY.0000058374.50240.BF
- Kurd SK, 2009, J AM ACAD DERMATOL, V60, P218, DOI 10.1016/j.jaad.2008.09.022
- Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7
- Rampton DS, 2011, J RHEUMATOL, V38, P43, DOI 10.3899/jrheum.110904
- Richards HL, 2005, BRIT J DERMATOL, V153, P1114, DOI 10.1111/j.1365-2133.2005.06817.x